Namaxir (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA and RNA synthesis. This reduces the proliferation of activated immune cells and cancer cells. Additionally, methotrexate increases extracellular adenosine, which has broad anti‑inflammatory effects.

The dose of methotrexate is individualized by the prescribing clinician based on the specific indication, patient weight, renal function and other clinical factors. Dosage regimens can vary widely, and any adjustments are made under medical supervision.

Methotrexate is classified as pregnancy category X because it is known to cause fetal malformations and miscarriage. It is contraindicated for women who are pregnant or may become pregnant unless effective contraception is used. Limited data exist for breastfeeding, and most guidelines advise against use while nursing.

To request Namaxir, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

For rheumatoid arthritis, methotrexate (Namaxir) is often the first‑line disease‑modifying antirheumatic drug (DMARD) and is less expensive than biologic agents such as TNF‑alpha inhibitors. In psoriasis, it offers rapid plaque clearance but requires laboratory monitoring, whereas newer biologics may have a more favorable side‑effect profile but higher cost.

Namaxir should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and do not freeze or shake the product. If temporary temperature excursions occur, follow the manufacturer’s stability guidelines before use.

Namaxir is supplied as a sterile solution for subcutaneous injection. The injection is typically given into the abdomen or thigh using a pre‑filled syringe or vial, following aseptic technique. Administration frequency (weekly, bi‑weekly, etc.) is determined by the treating physician.

Serious adverse events include severe liver toxicity or fibrosis, pulmonary fibrosis/interstitial pneumonitis, and profound bone‑marrow suppression that can lead to life‑threatening infections, anemia or bleeding. Patients should be educated to report persistent cough, shortness of breath, jaundice, or unexplained bruising immediately.

Namaxir is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate, patients with severe hepatic impairment, uncontrolled infections, and those with significant renal dysfunction (creatinine clearance <30 mL/min). Caution is also advised for patients with pre‑existing lung disease.